

# Agenda DISCO Investigator meeting November 12

## Welcome and presentation of participants

Sten

## Study update

Sten

### ESC Guidelines-impact on DISCO

Stefan

### Pearl study

Stefan

### Netherlands-update

Judith or Niels

### France-update

Christian S or Alain

### Denmark-update

Christian JT

## Neurologic follow-up and Prognostication

Tobias, Ing-Marie or Ewa

## Questions addressed by the sites

All

## Summary

# Study update

The background of the slide features abstract, overlapping geometric shapes in various shades of green, ranging from a light lime green to a dark forest green. These shapes are primarily located on the right side of the slide, creating a modern, layered effect. The left side of the slide is a solid, very light green, providing a clean backdrop for the text.




Cardiac arrests Screening-  
possible inclusion into DISCO

**947 patients**

since main study start March 2018

# Screening

**763** excluded patients




# OTHER and DOCTORS DECISION

- ▶ **ANGIO-DOCTORS DECISION**
- ▶ **UNWITNESSED**
- ▶ **ARRHYTHMIA  
PEA**
- ▶ **NON-CARDIAC  
HYPOXIA  
INTOXICATION**
- ▶ **DNR**
- ▶ **ADMITTED FROM OTHER HOSPITAL**

# Study Update

Included patients **184**

Sites



# ESC Guidelines-impact on DISCO


**Stefan James**

# 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

## Task Force Members:

**Jean-Philippe Collet (Chairperson) (France), Holger Thiele (Chairperson) (Germany),** Emanuele Barbato (Italy), Olivier Barthélémy (France), Johann Bauersachs (Germany), Deepak L. Bhatt (United States of America), Paul Dendale (Belgium), Maria Dorobantu (Romania), Thor Edvardsen (Norway), Thierry Folliguet (France), Chris P. Gale (United Kingdom), Martine Gilard (France), Alexander Jobs (Germany), Peter Jüni (Canada), Ekaterini Lambrinou (Cyprus), Basil S. Lewis (Israel), Julinda Mehilli (Germany), Emanuele Meliga (Italy), Béla Merkely (Hungary), Christian Mueller (Switzerland), Marco Roffi (Switzerland), Frans H. Rutten (Netherlands), Dirk Sibbing (Germany), George C. M. Siontis (Switzerland)






**Figure 9** Selection of non-ST-segment elevation acute coronary syndrome treatment strategy and

Risk Identification	Therapeutic strategy	Risk Category	I	A
<b>Very high risk</b> <ul style="list-style-type: none"> <li>• Haemodynamic instability</li> <li>• Cardiogenic shock</li> <li>• Recurrent/refractory chest pain despite medical treatment</li> <li>• Life-threatening arrhythmias</li> <li>• Mechanical complications of MI</li> <li>• Acute heart failure clearly related to NSTEMI-ACS</li> <li>• ST-segment depression &gt;1 mm/6 leads plus ST-segment elevation aVr and/or V1</li> </ul>	Immediate invasive (< 2 h)	<b>High risk</b> <ul style="list-style-type: none"> <li>• Established NSTEMI diagnosis</li> <li>• Dynamic new or presumably new contiguous ST/T-segment changes (symptomatic or silent)</li> <li>• Resuscitated cardiac arrest without ST-segment elevation or cardiogenic shock</li> <li>• GRACE risk score &gt;140</li> </ul>	An early invasive strategy within 24 h is recommended in patients with any of the following high-risk criteria: <ul style="list-style-type: none"> <li>• Diagnosis of NSTEMI suggested by the diagnostic algorithm recommended in Section 3</li> <li>• Dynamic or presumably new contiguous ST/T-segment changes suggesting ongoing ischaemia</li> <li>• Transient ST-segment elevation</li> <li>• GRACE risk score &gt;140.</li> </ul>	
	Early Invasive (< 24 h)		IIa	B

Delayed as opposed to immediate angiography should be considered among haemodynamically stable patients without ST-segment elevation successfully resuscitated after out-of-hospital cardiac arrest.

# COACT

ORIGINAL ARTICLE



## No. at Risk

Delayed	265	191	183	181	179	179	178
Immediate	273	183	178	176	176	176	176

# Invasive coronary treatment strategies for out-of-hospital cardiac arrest: a consensus statement from the European Association for Percutaneous Cardiovascular Interventions (EAPCI)/Stent for Life (SFL) groups

Marko Noc<sup>1</sup>, MD; Jean Fajadet<sup>2</sup>, MD; Jens F. Lassen<sup>3</sup>, MD; Petr Kala<sup>4</sup>, MD; Philip MacCarthy<sup>5</sup>, MD; Goran K. Olivecrona<sup>6</sup>, MD; Stephan Windecker<sup>7</sup>, MD; Christian Spaulding<sup>8\*</sup>, MD

## Abstract

Due to significant improvement in the pre-hospital treatment of patients with out-of-hospital cardiac arrest (OHCA), an increasing number of initially resuscitated patients are being admitted to hospitals. Because of the limited data available and lack of clear guideline recommendations, experts from the EAPCI and “Stent for Life” (SFL) groups reviewed existing literature and provided practical guidelines on selection of patients for immediate coronary angiography (CAG), PCI strategy, concomitant antiplatelet/anticoagulation treatment, haemodynamic support and use of therapeutic hypothermia. Conscious survivors of OHCA with suspected acute coronary syndrome (ACS) should be treated according to recommendations for ST-segment elevation myocardial infarction (STEMI) and high-risk non-ST-segment elevation -ACS (NSTEMI-ACS) without OHCA and should undergo immediate (if STEMI) or rapid (less than two hours if NSTEMI-ACS) coronary invasive strategy. Comatose survivors of OHCA with ECG criteria for STEMI on the post-resuscitation ECG should be admitted directly to the catheterisation laboratory. For patients without STEMI ECG criteria, a short “emergency department or intensive care unit stop” is advised to exclude non-coronary causes. In the absence of an obvious non-coronary cause, CAG should be performed as soon as possible (less than two hours), in particular in haemodynamically unstable patients. Immediate PCI should be mainly directed towards the culprit lesion if identified. Interventional cardiologists should become an essential part of the “survival chain” for patients with OHCA. There is a need to centralise the care of patients with OHCA to experienced centres.

# DISCO

Direct or Subacute  
Coronary angiography  
for Out of hospital  
cardiac arrest a  
randomized study


**A Randomized Pilot Clinical Trial of Early Coronary Angiography Versus No  
Early Coronary Angiography for Post-Cardiac Arrest Patients Without ST-  
Segment Elevation: The PEARL Study**

**Running Title:** *Kern et al.; Angiography in Resuscitated Patients Without ST Elevation*

Karl B. Kern, MD<sup>1</sup>; Peter Radsel, MD, PhD<sup>2</sup>; Jacob C. Jentzer, MD<sup>4</sup>; David B. Seder, MD<sup>3</sup>;  
Kwan S. Lee, MD<sup>1</sup>; Kapildeo Lotun, MD<sup>1</sup>; Rajesh Janardhanan, MD<sup>1</sup>; Dion Stub, MD, PhD<sup>5</sup>;  
Chiu-Hsieh Hsu, PhD<sup>6</sup>; Marko Noc, MD, PhD<sup>2</sup>

**Conclusions:** This underpowered study, when considered together with previous clinical trials, does not support early coronary angiography for comatose survivors of cardiac arrest without ST elevation. Whether early detection of occluded potential culprit arteries leads to interventions that improve outcomes requires additional study.

Kaplan-Meier survival estimates



Culprit identified in 46.9 vs 41.7%


## Primary EP

Composite of efficacy and safety measurements, including efficacy parameters of survival to discharge, favorable neurological status at discharge (Cerebral Performance Category < 2), echocardiographic measures of left ventricular ejection fraction >50% and a normal regional wall motion score of 16 within 24 hours of admission

Endpoint	Early coronary angiography (n=49)	No early coronary angiography (n=50)	P*
	Freq (%)	Freq (%)	
<b>1° Endpoint of Combined Efficacy and Adverse Events</b>	<b>27 (55.1%)</b>	<b>23 (46.0%)</b>	0.64
<b>Composite efficacy</b>	<b>36<sup>†</sup> (73.5%)</b>	<b>30<sup>†</sup> (60.0%)</b>	0.20
Survival to DC	27 (55.1%)	24 (48.0%)	0.55
Normal WMSI at admission	9 (19.6%) (n=46)	12 (25.5%) (n=47)	0.62
LVEF ≥50% at admission	19 (40.4%) (n=47)	16 (34.0%) (n=47)	0.67
Intact functional status at DC	25 (51.0%)	23 (46.0%)	0.69
<b>Composite Adverse Events</b>	<b>13 (26.5%)</b>	<b>13 (26.0%)</b>	1.00
Re-arrest	3 (6.1%)	3 (6.0%)	1.00
Pulmonary edema	3 (6.1%)	0 (0.0%)	0.12
Acute renal worsening	1 (2.0%)	2 (4.0%)	1.00
Bleeding	2 (4.1%)	0 (0.0%)	0.24
Hypotension	5 (10.2%)	5 (10.0%)	1.00
Pneumonia	4 (8.2%)	4 (8.0%)	1.00



Endpoint	Early coronary angiography (n=49)	No early coronary angiography (n=50)	P*
	Freq (%) / median (IQR)	Freq (%) / median (IQR)	
<b>Survival analysis</b> (median survival time in days; 95% CI)	66 (11, NA)	25 (8, NA)	0.78
Hazard ratio (95% CI)	0.93 (0.55, 1.55)	1.00	0.77
30-day survival (S(t)±se <sup>†</sup> )	0.55±0.07	0.46±0.07	0.36
180-day survival (S(t)±se)	0.45±0.08	0.40±0.08	0.66
<b>Cause of Death</b>			
Anoxic Brain Injury	16	17	1.00
Cardiovascular	6	6	1.00
Miscellaneous	2	6	0.27
<b>WMSI at DC</b>	2 (1-4) N=9	3 (1.5-4) N=8	0.59
1	4 (44.4%)	2 (25%)	
2	2 (22.2%)	1 (12.5%)	
3	0 (0%)	2 (25%)	
4	3 (33.3%)	3 (37.5%)	
<b>WMSI at 180 days post DC</b>	1 (1-1) N=4	2 (1-2) N=5	0.17
1	4 (100%)	2 (40%)	
2	0 (0%)	3 (60%)	
<b>CPC &lt;3 or MRS &lt;4</b>			
30 days post DC	19 (86.4%) (n=22)	16 (88.9%) (n=18)	1.00
180 days post DC	16 (100%) (n=16)	13 (100%) (n=13)	NA
<b>MMSE</b>			
At DC	27.0 (25-30) (n=17)	28.5 (27-30) (n=18)	0.69
180 days post DC	30.0 (29-30) (n=13)	30.0 (23-30) (n=11)	0.84
<b>Anxiety</b>			
At DC	6.0 (4-9) (n=16)	5.0 (1-12) (n=19)	0.70
180 days post DC	4.0 (1-5) (n=13)	1.0 (0-4) (n=11)	0.23
<b>Depression</b>			
At DC	3.0 (0.5-7.5) (n=16)	4.0 (1-8) (n=19)	0.78
180 days post DC	1.0 (0-3) (n=13)	2.0 (0-3) (n=11)	1.00
<b>MOCA</b>			
At DC	21.5 (18-22.5) (n=16)	25.0 (15-28) (n=17)	0.65
180 days post DC	26.5 (25-28.5) (n=12)	29.0 (27-30) (n=9)	0.13
<b>IQCODE</b>			
At DC	3.0 (2.75-3.19) (n=14)	3.0 (3-3.10) (n=12)	0.89
180 days post DC	3.0 (2.9-3.16) (n=12)	3.0 (3-3.8) (n=11)	0.15

The background features abstract, overlapping geometric shapes in various shades of green, ranging from light lime to dark forest green. These shapes are primarily located on the right side of the image, creating a modern, layered effect. The rest of the background is a solid, very light gray.

"To be conscious that you are ignorant of the facts is  
a great step to knowledge"

*Benjamin Disraeli*



# EUROPE

Netherlands, France, Denmark

# Netherlands

Niels van Royen & Judith Bonnes



# France

Christian Spaulding

# Denmark

Christian Juhl Terkelsen



# Follow-up DISCO trial

Ewa Wallin, Intensive care nurse, Phd, senior lecture

Ing-Marie Larsson, Intensive care nurse, Phd, senior lecture

Why do we need Follow-Up?



# Areas in the follow-up

- ▶ HRQoL
- ▶ Somatic health
- ▶ Fatigue
- ▶ Cognitive function
- ▶ Anxiety and depression
- ▶ "Daily life"
- ▶ Caregiver burden

# How do we perform the follow-up?

- Face-to-face follow up whenever possible
- If face-to-face follow up is impossible, a telephone follow-up is of course better than no follow up at all



# PRACTICAL ASPECTS

## *QUESTIONS?*

Thank you for your Good work

[Ing-marie.larsson@surgsci.uu.se](mailto:Ing-marie.larsson@surgsci.uu.se)

# Neurological prognostication in the DISCO-trial

Tobias Cronberg, Professor Neurology, Lund University

# Neurological prognostication in the DISCO-trial

- ▶ Clinical examination focused on the motor score, pupillary reflex and corneal reflex
- ▶ EEG, CT, MRI, SSEP and serum NSE are optional investigations
- ▶ Formal prognostication of all patients who are still in the ICU 96 hours after randomisation

In the DISCO trial the prognosis is considered *likely poor* if A, B and C criteria are fulfilled;

- A. Confounding factors such as severe metabolic derangement and lingering sedation has been ruled out
- B. The patient has no response or a stereotypic extensor response to bilateral central and peripheral painful stimulation at  $\geq 96$  hours after randomisation.
- c. At least two of the below mentioned signs of a poor prognosis are present:

## At least two of the below mentioned signs of a poor prognosis are present:

1. Bilateral absence of pupillary and corneal reflexes at 96h after CA or later
2. A prospectively documented early status myoclonus (within 48 hours)
3. A highly malignant EEG-pattern without reactivity to sound and painful stimulation.
4. CT brain with signs of global ischaemic injury, such as: generalised oedema with reduced grey/white matter differentiation and sulcal effacement **OR**  
MRI-brain with signs of global, diffuse, or bilateral multifocal ischaemic lesions.
5. Serial serum-NSE samples consistently higher than locally established levels associated with a poor outcome
6. Bilaterally Absent SSEP N20-responses more than 48 hours after randomisation.


# Highly malignant EEG-patterns

1. Suppressed background (amplitude  $<10\text{mV}$ , 100% of the recording) without discharges.
2. Suppressed background with superimposed continuous periodic discharges.
3. Burst-suppression (periods of suppression with amplitude  $<10\text{mV}$  constituting 50% of the recording) without discharges.
4. Burst-suppression with superimposed discharges.

# Why should prognostication be multimodal?

- ▶ All methods have pitfalls
- ▶ False positives reported with all methods
- ▶ Using multiple independent methods reduce the risk of errors by chance
- ▶ There is no room for mistakes

# The 2021 ERC/ESICM algorithm is multimodal





# Questions

Tobias.Cronberg@skane.se

Questions/Issues from all

# Summary